Prescribed medical cannabis in women with gynecologic malignancies: A single-institution survey-based study

Authors

Emily M. Webster, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale New Haven Hospital, New Haven, CT 06510, United States.
Ghanshyam S. Yadav, Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX 77030, United States.
Stefan Gysler, Hospital of the University of Pennsylvania / University of Pennsylvania, Philadelphia, PA 19104, United States.
Blair McNamara, UCSF Medical Center/University of California, San Francisco, San Francisco, CA 94143, United States.
Jonathan Black, The Center for Gynecologic Oncology, Miramar, FL 33027, United States.
Joan Tymon-Rosario, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale New Haven Hospital, New Haven, CT 06510, United States.
Burak Zeybek, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale New Haven Hospital, New Haven, CT 06510, United States.
Chanhee Han, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale New Haven Hospital, New Haven, CT 06510, United States.
Christopher K. Arkfeld, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale New Haven Hospital, New Haven, CT 06510, United States.
Vaagn Andikyan, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale New Haven Hospital, New Haven, CT 06510, United States.
Gulden Menderes, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale New Haven Hospital, New Haven, CT 06510, United States.
Gloria Huang, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale New Haven Hospital, New Haven, CT 06510, United States.
Masoud Azodi, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale New Haven Hospital, New Haven, CT 06510, United States.Follow
Dan-Arin Silasi, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale New Haven Hospital, New Haven, CT 06510, United States.
Alessandro D. Santin, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale New Haven Hospital, New Haven, CT 06510, United States.
Peter E. Schwartz, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale New Haven Hospital, New Haven, CT 06510, United States.
Elena S. Ratner, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale New Haven Hospital, New Haven, CT 06510, United States.
Gary Altwerger, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale New Haven Hospital, New Haven, CT 06510, United States.

Document Type

Article

Publication Title

Gynecologic oncology reports

Abstract

Research within a gynecologic oncology population has lagged behind the uptake in use of medical cannabis for symptom control. This study seeks to evaluate patient experience with prescribed medical cannabis obtained through licensed dispensaries in women with gynecologic malignancies. A 43-item survey exploring patient experience with medical cannabis was administered to women with gynecologic malignancies who used medical cannabis prescribed by a gynecologic oncologist. Thirty-six eligible patients were approached for consent, and 31 patients returned completed surveys (86%). Ninety-three percent had advanced or recurrent disease; 74% were receiving chemotherapy or immunotherapy. Eighty-three percent reported medical cannabis provided relief from cancer or treatment-related symptoms including decreased appetite (41%), insomnia (41%), neuropathy (41%), anxiety (35%), nausea (29%), joint pain (29%), bone pain (29%), abdominal pain (25%), and depression (19%). Eighty percent of patients reported medical cannabis worked the same or better than other traditional medications for management of their cancer or treatment-related symptoms, and 83% reported medical cannabis had an equivalent or better side effect profile. Of the subset of patients using medical cannabis for pain, 63% reported a reduction in opioid use. Patients perceive that medical cannabis was useful for relief of cancer and treatment-related symptoms, suggesting medical cannabis may be a reasonable alternative or adjunct therapy. Medical cannabis was well tolerated and may have the potential to improve neuropathic pain and decrease opioid use.

First Page

100667

DOI

10.1016/j.gore.2020.100667

Publication Date

11-1-2020

Identifier

33204797 (pubmed); PMC7653050 (pmc); 10.1016/j.gore.2020.100667 (doi); S2352-5789(20)30133-8 (pii)

This document is currently not available here.

Share

COinS